Recent advances in antimultiple myeloma drug development.
Recent advances in antimultiple myeloma drug development.
复制标题
抗多发性骨髓瘤药物开发的最新进展。
DOI：
10.4155/ppa.14.18
复制
发表时间：
2014-05
影响因子：
1.3
通讯作者：
Xie XQ
中科院分区：
文献类型：
--
作者：
Wang N;Bartlow P;Ouyang Q;Xie XQ
多发性骨髓瘤（MM）是第二常见的血液恶性肿瘤，其特征在于终末分化的血浆B细胞的异常增殖和凋亡能力的损害。特别是，高副蛋白血症和高钙血症导致的溶骨性骨病和肾功能衰竭已成为与MM肿瘤进展密切相关的主要严重后遗症。尽管引入了新的治疗方案，但有问题的神经病变、血小板减少症、耐药性和高MM复发率继续困扰着当前的治疗。在了解肿瘤坏死因子-α、蛋白酶体、PI 3 K和MARKs等信号通路和分子机制的基础上，新的化学制剂正在开发中。本文综述了多发性骨髓瘤治疗新药的最新专利和临床试验。此外，参与骨髓瘤细胞的增殖，存活和凋亡的重要信号通路将被讨论。
Multiple myeloma (MM) is the second most common hematological malignancy and is characterized by the aberrant proliferation of terminally differentiated plasma B cells with impairment in apoptosis capacity. Particularly, osteolytic bone diseases and renal failure resulting from hyperparaproteinemia and hypercalcemia have been the major serious sequelae that are inextricably linked with MM tumor progression. Despite the introduction of new treatment regimens, problematic neuropathy, thrombocytopenia, drug resistance and high MM relapse rates continue to plague the current therapies. New chemical agents are in development on the basis of understanding several signaling pathways and molecular mechanisms like tumor necrosis factor-α, proteasome, PI3K and MARKs. This review focuses on the most recent patents and clinical trials in the development of new medicine for the treatment of multiple myeloma. Furthermore, the important signaling pathways involved in the proliferation, survival and apoptosis of myeloma cells will be discussed.